Advanced search
1 file | 270.02 KB

Old and new adjuvants for hepatitis B vaccines

Author
Organization
Abstract
The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.
Keywords
Vaccine, Hepatitis B virus, Adjuvant, Adjuvant systems, Prophylaxis, IMMUNOSTIMULATORY PHOSPHOROTHIOATE OLIGODEOXYRIBONUCLEOTIDE, MONOPHOSPHORYL-LIPID-A, SURFACE-ANTIGEN, HEALTHY-ADULTS, VIRUS-INFECTION, HEPATOCELLULAR-CARCINOMA, IMMUNOLOGICAL RESPONSE, CANDIDATE VACCINE, IMMUNE-RESPONSE, UNITED-STATES

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 270.02 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Leroux-Roels, Geert. 2015. “Old and New Adjuvants for Hepatitis B Vaccines.” Medical Microbiology and Immunology 204 (1): 69–78.
APA
Leroux-Roels, G. (2015). Old and new adjuvants for hepatitis B vaccines. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 204(1), 69–78.
Vancouver
1.
Leroux-Roels G. Old and new adjuvants for hepatitis B vaccines. MEDICAL MICROBIOLOGY AND IMMUNOLOGY. 2015;204(1):69–78.
MLA
Leroux-Roels, Geert. “Old and New Adjuvants for Hepatitis B Vaccines.” MEDICAL MICROBIOLOGY AND IMMUNOLOGY 204.1 (2015): 69–78. Print.
@article{6830217,
  abstract     = {The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.},
  author       = {Leroux-Roels, Geert},
  issn         = {0300-8584},
  journal      = {MEDICAL MICROBIOLOGY AND IMMUNOLOGY},
  keywords     = {Vaccine,Hepatitis B virus,Adjuvant,Adjuvant systems,Prophylaxis,IMMUNOSTIMULATORY PHOSPHOROTHIOATE OLIGODEOXYRIBONUCLEOTIDE,MONOPHOSPHORYL-LIPID-A,SURFACE-ANTIGEN,HEALTHY-ADULTS,VIRUS-INFECTION,HEPATOCELLULAR-CARCINOMA,IMMUNOLOGICAL RESPONSE,CANDIDATE VACCINE,IMMUNE-RESPONSE,UNITED-STATES},
  language     = {eng},
  number       = {1},
  pages        = {69--78},
  title        = {Old and new adjuvants for hepatitis B vaccines},
  url          = {http://dx.doi.org/10.1007/s00430-014-0375-9},
  volume       = {204},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: